A significant response to sorafenib in a woman with advanced lung adenocarcinoma and a BRAF non-V600 mutation

Lung adenocarcinoma includes recurrent activating oncogenic mutations (EGFR, EML4-ALK, ROS1) that have been associated with response to EGFR and ALK inhibitors. Platinum-based chemotherapy is the standard therapy for non-oncodrivers population. Sorafenib is a small molecule that blocks the activatio...

Full description

Saved in:

Bibliographic Details
Published in:	Anti-cancer drugs Vol. 26; no. 9; pp. 1004 - 1007
Main Authors:	Sereno, María, Moreno, Victor, Moreno Rubio, Juan, Gómez-Raposo, César, García Sánchez, Sagrario, Hernández Jusdado, Rebeca, Falagan, Sandra, Zambrana Tébar, Francisco, Casado Sáenz, Enrique
Format:	Journal Article
Language:	English
Published:	England 01-10-2015
Subjects:	Adenocarcinoma - drug therapy Adenocarcinoma - genetics Antineoplastic Agents - therapeutic use Female Humans Lung Neoplasms - drug therapy Lung Neoplasms - genetics Middle Aged Mutation Niacinamide - analogs & derivatives Niacinamide - therapeutic use Phenylurea Compounds - therapeutic use Proto-Oncogene Proteins B-raf - genetics
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Lung adenocarcinoma includes recurrent activating oncogenic mutations (EGFR, EML4-ALK, ROS1) that have been associated with response to EGFR and ALK inhibitors. Platinum-based chemotherapy is the standard therapy for non-oncodrivers population. Sorafenib is a small molecule that blocks the activation of C-RAF, B-RAF, c-KIT, FLT-3, RET, VEGFR-2, VEGFR-3 and PDGFR approved for advanced renal cell and hepatocellular carcinoma (b, c). Many studies have evaluated sorafenib in advanced non-small-cell lung cancer (NSCLC), with different results. We present a case report of a patient with NSCLC and the BRAF G469R mutation who showed a dramatic response to sorafenib.
Bibliography:	ObjectType-Case Study-2 SourceType-Scholarly Journals-1 ObjectType-Feature-4 content type line 23 ObjectType-Report-1 ObjectType-Article-3 ObjectType-Article-1 ObjectType-Feature-2
ISSN:	0959-4973 1473-5741
DOI:	10.1097/CAD.0000000000000277